Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the osteoarthritis drug market reached $3.5 billion in 2002. According to the new Pharmacor study entitled Osteoarthritis, market growth will be driven by second-generation, selective cyclooxygenase (COX)-2 inhibitors such as Pfizer's Bextra, Merck's Arcoxia, and Novartis's Prexige. The study forecasts that the selective COX-2 inhibitor class will reach $2.8 billion in sales for osteoarthritis in 2012.

"Pfizer's Bextra launched in the United Sates before any of the other second-generation, selective COX-2 inhibitors in development, and that first- to-market status will help it garner a greater share of the osteoarthritis market compared with other emerging agents in this class," said Melissa Garland, analyst at Decision Resources. "By 2012, Bextra will capture nearly 27% of the selective COX-2 inhibitor market, with sales totaling $750 million, second only to its predecessor, Celebrex."

About Osteoarthritis

Osteoarthritis, a noninflammatory degenerative joint disease, is the most common form of arthritis and is one of the most frequent causes of physical disability in adults.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Will Medicare Reform Be A Gold Mine For The Pharmaceutical And Managed Care Industries?

View Now